Primary Record
MRS 1754
- In stock
- 9,688 g
- Purity
- 99.3 %
- CAS
- 264622-58-4
Compound Identifiers & Properties
- CAS
- 264622-58-4
- PubChem CID
- 6603931
- SMILES
- CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)NC4=CC=C(C=C4)C#N
- Canonical SMILES
- CCCn1c(=O)c2[nH]c(-c3ccc(OCC(=O)Nc4ccc(C#N)cc4)cc3)nc2n(CCC)c1=O
Names & Synonyms
- MRS 1754
- MRS1754
- 264622-58-4
- MRS-1754
- RefChem:827519
- 7E435V2DAH
- Lopac-M-6316
- D01QYQ
- D0NE5P
- ATL-GW-8
- CHEMBL273807
- UNII-7E435V2DAH
- Lopac0_000729
- GTPL449
- GTPL453
- ATL-GW-22
- MLS002153324
- DTXSID80424967
- AC1O7G54
- orb1308009
- SCHEMBL1222380
- SCHEMBL3395773
- CHEMBL1628266
- [3H]MRS1754
- CHEBI:93269
- CTK8E7916
- AOB5542
- ATL-618
- ATL-844
- DTXCID00375801
- [3H]-MRS1754
- AJBBEYXFRYFVNM-UHFFFAOYSA-N
- C26H26N6O4
- GLXC-06634
- HMS2230A06
- HMS3268F13
- HMS3373J21
- HMS3742I17
- BCP31360
- EX-A7320
- MRS1754?
- PKA62258
- ZINC4475274
- BDBM50086170
- MFCD09971130
- NCGC00015689-01
- s6693
- N-(4-Cyanophenyl)-2-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)phenoxy)acetamide
- AKOS024457276
- CCG-204814
- CID6603931
- EX-3306
- CID:6603931
- MRS-1754; MRS 1754
- NCGC00015689-02
- NCGC00015689-03
- NCGC00015689-04
- NCGC00094075-01
- NCGC00094075-02
- NCGC00094075-03
- AS-80780
- DA-75755
- HY-14121
- SMR001230737
- SID:181285846
- N-(4-cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide
- B7173
- CS-0003210
- EU-0100729
- J1.293.769E
- 8-[4-[( oxy]phenyl]-1,3-di xanthinehydrate
- G13686
- M 6316
- C423842
- L000415
- SR-01000076213
- A1010179
- N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide
- SR-01000076213-1
- BRD-K72024482-001-01-3
- Q27087766
- Acetamide, N-(4-cyanophenyl)-2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-
- A2B adenosine receptor antagonists, Adenosine/Ortho-McNeil
- N-(4-cyanophenyl)-2-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)phenoxy)acetamide
- A2B adenosine receptor antagonists (oral, asthma/diabetes), Clinical Data
- Acetamide, N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)-
- Acetamide, N-(4-cyanophenyl)-2-(4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)-
- N-(4-cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)phenoxy]acetamide
- 8-(4-(((4-cyanophenyl)carbamoylmethyl)oxy)phenyl)-1,3-di(ni-propyl)xanthine
- 8-[4-[((4-Cyanophenyl)carbamoylmethyl)oxy]phenyl]-1,3-di(n-propyl)xanthine
- 8-[4-[((4-Cyanophenyl)carbamoylmethyl)oxy]phenyl]-1,3-di(n-propyl)xanthine hydrate
- A2B adenosine receptor antagonists (oral, asthma/diabetes), Adenosine Therapeutics
- N-(4-cyanophenyl)-2-(4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy)acetamide
- N-(4-cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-9H-purin-8-yl)phenoxy]acetamide
- (4-Cyano-phenyl)-carbamic acid 4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-phenyl ester
- Acetamide,N-(4-cyanophenyl)-2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-
- N-(4-Cyano-phenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-phenoxy]-acetamide
- N-(4-Cyano-phenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-phenoxy]-acetamide(MRS-1754)
- N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide
- N-(4-Cyanophenyl)-2-[4-(1,3-dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purine-8-yl)phenoxy]acetamide
- N-(4-Cyanophenyl)-2-[4-(1,3-dipropyl-2,6-dioxo-3,7-dihydro-1H-purine-8-yl)phenoxy]acetamide